A tailor-made programme, exclusively for invited members of Daiichi-Sankyo scientific and medical team
This training programme is exclusively for invited members members of the Daiichi-Sankyo scientific and medical team. Our goal with this exciting programme is to update you to the best possible level, to prepare for the presentation of the results of the CLEAR Outcomes trial in March 2023.
The Scientific Director of the programme is former President of the EAS, Prof Alberico L. Catapano, Milan, Italy. Here, in the video below, he describes what you will learn from it.
In our specially created programme, the faculty – selected experts from the EAS scientific community – take you through the development of new approaches to lipid lowering and cardiovascular risk, presenting the most recent data, and identifying emerging trends. We will discuss together what we can expect from the randomised clinical trial with cardiovascular outcomes that will be presented at the meeting of the American College of Cardiology 2023.
The programme is in two parts:
- Part 1: Available now. A short online curriculum comprising five on-demand modules for invited participants to work through prior to…
- Part 2: A meeting 13-14 February, 2023. Separate registration is required, invited participants only.
Sign in required.
At your own pace, work through these online modules to refresh your knowledge in the area in advance of the February meeting.
Separate registration required, invited participants only.
Frankfurt, 13-14 Feb 2023. A deep dive into the use of bempedoic acid in cardiovascular disease therapy, including sessions to challenge you about what you have learned and how you interpret all of the information that has been discussed.
The full programme is as follows:
13 Feb | |
14:00 | Welcome & Opening Kausik Ray & Alberico L. Catapano |
14:10 | Lipid lowering and diabetes Lale Tokgozoglu |
14:50 | Lipid Lowering and CRP: how important? Maciej Banach |
15:30 | Break |
15:50 | Bempedoic Acid: mechanism of action Stephen Pinkosky |
16:30 | Genetic data Alberico L Catapano |
17:10 | Break |
17:30 | Bempedoic Acid: a bird’s-eye view of clinical development Bill Sasiela |
18:10 | Interaction with statins Alberico L. Catapano |
18:50 | Summary & Wrap up Kausik Ray & Alberico L. Catapano |
14 Feb | |
08:00 | Welcome & Opening Kausik Ray & Alberico Catapano |
08:10 | CLEAR Outcomes – study design, its implications and what are we expecting (CTT meta-analysis) Kausik Ray |
08:50 | Efficacy & safety Ulrich Laufs |
09:30 | Break |
09:50 | Place in therapy: Round Table All EAS Speakers |
10:55 | Role play – FAQs – what to say when faced by a non-believer Main topics: • Anti-inflammatory effects • Efficacy & safety • LDL reduction • The Clear Outcome data: only for statin intolerant patients? |
12:00 | Break |
12:15 | Question time All EAS Speakers |
12:45 | Closing remarks Kausik Ray & Alberico Catapano |